

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



Sub C1
B1

~~13. A method for inhibiting cancer metastasis formation in a patient in need thereof, the method comprising administering to the patient a cancer metastasis formation inhibiting effective amount of N-acetyl-cysteine and doxorubicin.~~

14. The method according to claim 13, wherein the N-acetyl-cysteine is administered in an amount between 100 mg and 6 g per day.

15. The method according to claim 13, wherein the doxorubicin is administered in an amount between 1 and 50 mg per dose.--

REMARKS

Claims 10-12 are currently pending. In this Response, applicants cancel claims 10-12 and add new claims 13-15. Claims 13-15 are presented for reconsideration.

Claims 10-12 are rejected under 35 USC §102(b) as being anticipated by Myers, Jr. (U.S. Patent No. 4,331,648) or Doroshov (1981) or Myers (1983) or Freeman (1980). The Examiner takes the position that each of the cited references discloses the use of doxorubicin and N-acetyl-cysteine in the treatment of cancer in dosage ranges that overlap with the ranges claimed in the present case. The Examiner admits that these references teach the use of N-acetyl-cysteine to reduce the cardiotoxicity of the doxorubicin administered for cancer treatment. However, the Examiner takes the position, because the dosages of doxorubicin and N-acetyl-cysteine claimed by applicant and used in the prior art overlap, the claimed method would be inherent in the prior art methods.


be inhibited by administering doxorubicin and N-acetyl-cysteine. Thus, those of skill in the art would not have administered these compounds to a patient in need of cancer metastasis formation inhibition before the present invention. The present invention is no more "inherent" in the treatments disclosed in the references than any other "second medical use". The fact that countless U.S. Patents have issued on second medical uses shows that the Examiner's "inherency" argument is flawed.

The issue in the present case is whether any reference show that cancer metastasis formation can be inhibited in a patient in need thereof by administering the two compounds of the present claims. Clearly, the Examiner has not shown any such evidence. Therefore, the present invention is clearly patentable over the cited references.

In the event this paper is not timely filed, applicants hereby petition for an appropriate extension of time. The fee for this extension may be charged to our Deposit Account No. 01-2300, along with any other additional fees which may be required with respect to this paper.

Respectfully submitted,

Arent Fox Kintner Plotkin & Kahn


Richard J. Berman
Attorney for Applicant(s)
Registration No. 39,107

Atty. Docket No. P8903-8035

1050 Connecticut Avenue, NW
Suite 400
Washington, D.C. 20036-5339
(202) 638-5000

Enclosure: Cancer, Principles & Practice of Oncology
RJB/ccd

In order to more clearly point out the differences between the present invention and the cited references, applicants have canceled claims 10-12 and have added new claims 13-15. As the Examiner can see, the new claims are directed to methods for inhibiting cancer metastasis formation in a patient in need thereof. This change in claim language clearly distinguishes the present invention from the cited references.

Applicants note that each of the cited references teach the administration of doxorubicin and N-acetyl-cysteine to cancer patients. However, it is clear that in each of these references, doxorubicin is administered for the treatment of tumors and N-acetyl-cysteine is administered to protect against cardiac damage. See column 2, lines 1-31 of Myers, Jr.; page 1053 of Doroshow; page 53 of Myers; and page 168 of Freeman.


The treatment of cancer metastasis is different than the treatment of cancer tumors. See, for example, the attached copy of the Table of Contents from the book *Cancer, Principles & Practice of Oncology*. As the Examiner can see, chapters 8 and 61 are completely dedicated to the principles and treatment of metastatic cancer, while chapters 22-49 deal with cancer tumors.

Normally there is absolutely no correlation between successful treatment of cancer metastasis and successful treatment of cancer tumors with the same agent. Agents which are useful in preventing the spread of cancer (i.e., cancer metastasis) are not necessarily useful for the treatment of a tumor (e.g., to shrink the size of the tumor).

As the Examiner knows, the discovery of a new use for a known composition based on unknown properties of the composition is patentable to the discoverer of the method of use. See, for example *In re Hack*, 114 USPQ 161 (CCPA 1957). In this case, before the present invention, there was absolutely no evidence that cancer metastasis formation could

CANCER

Principles & Practice of Oncology



4th Edition



*J. B. LIPPINCOTT COMPANY
Philadelphia*

Project Editor: Dina K. Rubin
Indexer: Sandra King
Design Coordinator: Doug Smock
Production Manager: Caren Erlichman
Production Coordinator: Sharon McCarthy
Compositor: Tapsco Incorporated
Printer/Binder: Courier Book Company/Westford
Color Insert Printer: Village Craftsmen/Princeton Polychrome Press

4th Edition

Copyright © 1993, by J. B. Lippincott Company.
Copyright © 1989, 1985, 1982 by J. B. Lippincott Company.
All rights reserved. No part of this book may be used or reproduced in any manner whatsoever without written permission except for brief quotations embodied in critical articles and reviews. Printed in the United States of America. For information write J. B. Lippincott Company, 227 East Washington Square, Philadelphia, Pennsylvania 19106.

6 5 4 3 2 1

Library of Congress Cataloging in Publications Data

Cancer: principles and practice of oncology/[edited by] Vincent T. DeVita, Jr., Samuel Hellman, Steven A. Rosenberg; 214 contributors.—4th ed.

p. cm.
Includes bibliographical references.
Includes index.

ISBN 0-397-51214-7 (one-vol. ed.)

ISBN 0-397-51321-6 (two-vol. set)

ISBN 0-397-51322-4 (vol. 1)

ISBN 0-397-51323-2 (vol. 2)

ISSN 0892-0567

1. Cancer. 2. Oncology. I. DeVita, Vincent T., Jr. II. Hellman, Samuel.
III. Rosenberg, Steven A.

The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

CONTENTS

PART 1

PRINCIPLES OF ONCOLOGY 1

1

Principles of Molecular Cell Biology of Cancer: Introduction to Methods in Molecular Biology 3

SUSAN VANDE WOUDE
GEORGE F. VANDE WOUDE

Structure of DNA 3
Gene Expression 5
DNA Structural Analysis 5
Detection of Genes and Gene Products 9
Isolation and Characterization of Genes 11
Characterization of the Human Genome 14
Models Using Recombinant DNA Technology 16
Implications for Oncology 17
Glossary of Terms Used in Molecular Biology
and Oncogene Research 18

Molecular Markers in Cancer Diagnosis	93
Techniques for Detection of Molecular Markers in Cancer Diagnosis	95
Molecular Approaches to Diagnosis in Selected Cancers	100
Considerations for the Future	110

7

<i>Principles of Molecular Cell Biology of Cancer: Growth Factors</i>	114
---	-----

JOHN MENDELSON
MARC E. LIPPMAN

Autocrine Stimulation	114
Growth Factors and Their Receptors	116
Growth Factors and Malignancy	119
Specific Growth Factors	120
Growth Inhibitory Cytokines	126
Growth Factors and Their Receptors as Targets for Anticancer Therapy	127

8

<i>Principles of Molecular Cell Biology of Cancer: Cancer Metastasis</i>	134
--	-----

LANCE A. LIOTTA
WILLIAM G. STETLER-STEVENSON

The Clinical Significance of Invasion and Metastasis	134
Heterogeneity of the Metastatic Phenotype	135
Multiple Gene Products Are Involved in the Complex Metastatic Cascade	136
Circulating Tumor Cell Arrest and Extravasation	137
Metastasis Organ Distribution	137
Basement Membrane Disruption During Transition From In Situ to Invasive Tumors	139
Three-Step Theory of Invasion	139
Laminin Receptors	140
RGD Recognition Receptors (Integrins)	140
Cadherins: Role of Cell-Cell Adhesion in Tumor-Cell Invasion	140
Tumor-Cell Motility Factors	140
Proteinases and Tumor-Cell Invasion: From Correlation to Causality	141
Natural Proteinase Inhibitors Are Invasion Suppressors	143
Angiogenesis and Tumor Invasion Are Functionally Related	144
Metastasis and Tumorigenicity Can Be Under Separate Genetic Control	145
Metastasis Suppressor Genes	146
New Strategies for Metastasis Diagnosis and Therapy	146

9

<i>Epidemiology of Cancer</i>	150
-------------------------------	-----

JOSEPH F. FRAUMENI, JR. SUSAN S. DEVESA
ROBERT N. HOOVER LEO J. KINLEN

Historical Perspective	150
Aims of Epidemiology	151
Descriptive Studies	151
Patterns of Cancer Occurrence	154

14***Principles of Surgical Oncology***

STEVEN A. ROSENBERG

238

Historical Perspective 238

The Operation 239

Roles for Surgery 242

15***Principles of Radiation Therapy***

SAMUEL HELLMAN

248

Physical Considerations 248

Biologic Considerations 255

Tumor Radiobiology 264

Clinical Considerations 268

**16*****Principles of Chemotherapy***

276

VINCENT T. DEVITA, JR

History 276

Chemotherapy As Part of the Initial Treatment of Cancer 276

Clinical Endpoints in Evaluating Response to Chemotherapy 277

Principles Governing the Use of Combination Chemotherapy 278

Impact of the Goldie-Coldman Hypothesis on Design of Clinical Trials
Using Combination Chemotherapy 279

Response to Chemotherapy Is Affected by the Biology of Tumor Growth 280

Biochemical Resistance to Chemotherapy Is the Major Impediment
to Successful Treatment 281

Concept of Dose Intensity 283

In Vitro Tests to Select Chemotherapeutic Agents for Individualized Treatment 286

Cancer Drug Development 286

Early Clinical Trials of Antitumor Agents 288

Overcoming the Limitations of Cancer Treatment 289

17***Principles and Applications of Biologic Therapy***

293

STEVEN A. ROSENBERG

Basic Principles of Tumor Immunology 293

Immunotherapy 305

18**Anticancer Drugs**

BRUCE A. CHABNER

325

SECTION 1 Cancer Drug Discovery and Development 328

MICHAEL R. GREVER

BRUCE A. CHABNER

Drug Discovery 329

Drug Development 337

Conclusion 339

SECTION 2 Mechanisms of Antineoplastic Drug Resistance 340

CHARLES S. MORROW

KENNETH H. COWAN

General Mechanisms of Resistance to Antineoplastic Drugs 341

Resistance to Multiple Drugs 342

Approaches for the Prevention or Reversal of Clinical Drug Resistance 344

SECTION 3 Investigational Agents 349

MICHAEL J. HAWKINS

Amsacrine 349

Topoisomerase I Inhibitors 351

Anthrapyrazoles 353

Retinoids 354

SECTION 4 Antimetabolites 358

EDWARD CHU

CHRIS H. TAKIMOTO

Antifolates 358

Fluoropyrimidines 362

Cytarabine 365

Purine Analogs 369

Adenosine Analogs 370

SECTION 5 Antitumor Antibiotics 374

BRUCE A. CHABNER

CHARLES E. MYERS

Bleomycin 374

Anthracyclines 376

Mitomycin C 381

Dactinomycin 382

Mithramycin 383

SECTION 6 Miscellaneous Agents 385

BRUCE A. CHABNER

Hexamethylmelamine 385

Dacarbazine 385

Procarbazine 386

L-Asparaginase 387

SECTION 7	Platinum Analogs	390
	EDDIE REED	
	Chemistry	390
	Methods of Measurement of Platinum-DNA Adducts	391
	Mechanism of Action	392
	Determinants of Sensitivity and Resistance	393
	Clinical Pharmacokinetics and Drug Administration	394
	Toxicity	396

SECTION 8	Alkylating Agents	400
	NATHAN A. BERGER	
	Nitrogen Mustard	401
	Melphalan	402
	Chlorambucil	403
	Busulfan	403
	Cyclophosphamide	403
	Ifosfamide	405
	4-Hydroperoxycyclophosphamide	405
	Nitrosoureas	405
	Thiotepa	406

SECTION 9	Anticancer Drugs Derived From Plants	409
	ROSS C. DONEHOWER	
	ERIC K. ROWINSKY	
	Vinca Alkaloids	409
	Epipodophyllotoxins	412
	Taxol	414
	Mechanism of Action	415

19

Design and Conduct of Clinical Trials	418
--	------------

RICHARD SIMON

Study Objectives	419
Patient Eligibility	419
Endpoint	420
Treatment Allocation	420
Size and Duration of the Study	424
Epidemiology of Clinical Trials	431
Data Management	432
Ethics	432
Analysis	433
Reporting Results of Clinical Trials	436
Meta-analysis	438

PART 2

PRACTICE OF ONCOLOGY 441

20

Cancer Prevention 443

SECTION 1 Dietary Fat and Cancer 443

PETER GREENWALD
CAROLYN CLIFFORD

Epidemiologic Evidence 444

Experimental Evidence 446

Clinical Metabolic Studies 446

Clinical Intervention Studies 447

Alcohol and Cancer 448

Conclusion 448

SECTION 2 Dietary Fiber and Cancer 450

PETER GREENWALD

Dietary Fiber and Colorectal Cancer 451

Dietary Fiber and Breast Cancer 454

Dietary Fiber and Other Cancers 455

Achieving the Guidelines for Dietary Fiber 455

SECTION 3 Micronutrients and Chemoprevention 457

PETER GREENWALD

Epidemiologic Evidence 457

Mechanisms of Carcinogenesis and Chemoprevention Research 458

Biologic Markers 459

The Chemoprevention Program at the NCI 459

Clinical Chemoprevention Research 459

Future Directions 462

SECTION 4 Retinoids and Carotenoids 464

JULIE E. BURING

CHARLES H. HENNEKENS

Vitamin A Analogs and Precursors 464

Retinoids 464

Carotenoids 466

The Need for Randomized Trials 469

Ongoing Trials 469

Conclusion 470

SECTION 5 Hormones 474

BRIAN E. HENDERSON

LESLIE BERNSTEIN

RONALD ROSS

Oral Contraceptives 475

Hormone Replacement Therapy 476

SECTION 3	Cancer Markers 531	
	MORTON K. SCHWARTZ	
	Serum Markers 532	
	Multiple Marker Panels 539	
	Body Fluids Other Than Blood 540	
	Nuclear Magnetic Resonance 540	
	Cost and Acceptance of Using Tumor Markers 540	
SECTION 4	Interventional Radiology in Oncology 542	
	DONALD L. MILLER	
	JOHN L. DOPPMAN	
	Percutaneous Biopsy for Cancer Diagnosis 543	
	Cancer Treatment 545	
	Adjuncts in the Management of Cancer Patients 548	
SECTION 5	Vascular Access and Other Specialized Techniques of Drug Delivery 556	
	H. RICHARD ALEXANDER	
	Patient Selection and Preoperative Preparation 556	
	Catheter Selection 556	
	Technique of Insertion 558	
	Routine Postoperative Maintenance 559	
	Complications 559	
	Drug Delivery Systems 562	
	Conclusions 562	
SECTION 6	Cancer Screening 564	
	ANTHONY B. MILLER	
	General Principles of Screening 564	
	Screening for Cervical Cancer 565	
	Screening for Breast Cancer 567	
	Screening for Colorectal Cancer 569	
	Other Screening Programs 569	
	Future Perspectives 572	

22

Cancer of the Head and Neck 574

SECTION 1	Tumors of the Nasal Cavity and Paranasal Sinuses, Nasopharynx, Oral Cavity, and Oropharynx 574	
	STIMSON P. SCHANTZ	
	LOUIS B. HARRISON	
	WAUN KI HONG	
	Anatomy 574	
	Pathology 575	
	Natural History 576	
	Staging and Screening 578	
	Treatment 579	
	Principles of Chemoprevention of Upper Aerodigestive Tract Cancers 589	
	Nasal Cavity and Paranasal Sinuses 592	

Treatment Results	595
Nasopharynx	597
Oral Cavity	604
Oropharynx	613

SECTION 2 Tumors of the Larynx and Hypopharynx 631

ROY B. SESSIONS	
LOUIS B. HARRISON	
WAUN KI HONG	
Larynx	631
Hypopharynx	647

SECTION 3 Tumors of the Salivary Glands and Paragangliomas 655

ROY B. SESSIONS	
LOUIS B. HARRISON	
WAUN KI HONG	
Anatomy	655
Etiology, Pathology, and Classification	657
Natural History, Behavior, and Treatment	660
Clinical Evaluation and Workup	661
Treatment of Major Salivary Gland Tumors	661
Minor Salivary Gland Tumors	664
Specific Treatment and Special Situations	666
Paragangliomas	666

23

Cancer of the Lung 673

SECTION 1 Non-Small Cell Lung Cancer 673

ROBERT J. GINSBERG	
MARK C. KRIS	
JOHN G. ARMSTRONG	
Epidemiology	673
Biology of Lung Cancer	675
Pathology of Lung Cancer	676
Clinical Features	680
Staging of Lung Cancer	682
Diagnostic and Staging Procedures	682
Extent of Disease Evaluation	686
Pretreatment Prognostic Factors	688
Occult Lung Cancer	689
Lung Cancer Screening	689
Surgery for Non-Small Cell Lung Cancer	690
Adjuvant Therapies After Surgical Resection	697
Preoperative (Induction, Primary, Neoadjuvant) Therapies	699
Primary Radiotherapy for Lung Cancer	702
Chemotherapy for Lung Cancer	709
Immunotherapy of Non-Small Cell Lung Cancer	713
Palliation of Lung Cancer	713

SECTION 2	Small Cell Lung Cancer	723
	DANIEL C. IHDE	
	HARVEY I. PASS	
	ELI J. GLATSTEIN	
	Epidemiology and Etiology	723
	Pathology of Small Cell Lung Cancer	723
	Cellular and Molecular Biology	724
	Clinical Features	725
	Staging Evaluation and Prognostic Factors	727
	Treatment of Small Cell Carcinoma of the Lung	730

24

Neoplasms of the Mediastinum	759
J.C. ROSENBERG	
Anatomic Considerations	759
Diagnosis	760
Thymic Neoplasms	763
Germ Cell Tumors	770
Neurogenic Tumors	772
Soft Tissue Tumors	773

25

Cancer of the Esophagus	776
JACK A. ROTH	ALLEN S. LICHTER
JOE B. PUTNAM, JR	ARLENE A. FORASTIERE
Incidence and Epidemiology	776
Rare Cancers of the Esophagus	777
Anatomy	778
Clinical Presentation	780
Natural History and Patterns of Spread	782
Therapy for Cancer of the Esophagus	782
Adenocarcinoma of the Esophagus	793
Radiation Therapy in the Treatment of Esophageal Cancer	795
Combined Chemotherapy and Radiation Therapy Followed by Surgery	804
Chemotherapy	805
Palliation for Carcinoma of the Esophagus	808

26

Cancer of the Stomach	818
H. RICHARD ALEXANDER	
DAVID P. KELSEN	
JOEL E. TEPPER	
Epidemiology	818
Etiology and Pathogenesis	819
Anatomic Considerations	820

Pathology and Tumor Biology	822
Clinical Presentation	825
Treatment of Localized Disease	829
Treatment of Advanced Gastric Cancer	838
Conclusions	844

Cancer of the Pancreas

MURRAY F. BRENNAN
TIMOTHY J. KINSELLA
EPHRAIM S. CASPER

849

- Epidemiologic Considerations 849
- Etiologic Factors 849
- Anatomic Considerations 850
- Pathologic Classification 851
- Clinical Features 852
- Treatment of Localized Disease 856
- Treatment for Localized Unresectable and Metastatic Disease 862
- Systemic Therapy 868
- Summary 877
- Pain in Patients With Pancreas Cancer 877

28

Hepatobiliary Neoplasms

883

MICHAEL T. LOTZE
JOHN C. FLICKINGER
BRIAN I. CARR

- Lobar Anatomy and Physiology 883
- Liver Regeneration 884
- Reticuloendothelial System and Immune Function 885
- Hepatocellular Carcinoma 885
- Tumor Classification 887
- Workup of Hepatic Tumors 888
- Principles of Surgical Resection and Transplantation 891
- Radiobiology of the Hepatobiliary System 894
- Hepatocellular Carcinoma 894
- Hepatoblastoma 900
- Cancer of the Biliary System 900
- Carcinoma of the Gallbladder 906
- Other Tumors of the Liver 907

29

Cancer of the Small Intestine

915

DANIEL G. COIT

- Etiology 915
- Pathology 916

30

Colon Cancer 929

ALFRED M. COHEN

BRUCE D. MINSKY

RICHARD L. SCHILSKY

Anatomy 929

Epidemiology 931

Etiology 931

Primary Prevention 932

Secondary Prevention 932

Clinical Risk Factors for Colorectal Cancer 932

Diagnosis 935

Screening 935

Pathology 937

Spread of Colorectal Cancer 938

Staging and Prognostic Features 939

Treatment of Precancerous Colorectal Disease 945

Treatment of Potentially Curable Colon Cancer 947

Specific Management Problems in Colon Cancer 949

Adjuvant Therapies 951

Treatment of Initially Advanced Colon Cancer 959

Follow-up After Potentially Curative Therapy 960

Treatment of Recurrent or Metastatic Cancer 960

Miscellaneous Colorectal Tumors 967

31

Rectal Cancer 978

ALFRED M. COHEN

BRUCE D. MINSKY

MICHAEL A. FRIEDMAN

Anatomy 978

Diagnosis 978

Treatment of Resectable Rectal Cancer 980

Treatment of Invasive Rectal Cancer by Local Approaches 982

Results of Treatment of Rectal Cancer 984

Management Problems in Rectal Cancer 985

Radiation Therapy Alone for Resectable Cancer 985

Sphincter-Saving Adjuvant Therapies for Rectal Cancer 986

Adjuvant Radiation Therapy for Resectable Rectal Cancer 988

Radical Surgery and Adjuvant Chemotherapy Versus

Chemoradiation Therapy 994

Control of Locally Advanced and Unresectable Rectal Cancer 997

Follow-up After Potentially Curative Treatment 1001

Treatment of Recurrences 1001

32

Cancer of the Anal Region 1006

BRENDA SHANK

ALFRED M. COHEN

DAVID KELSEN

Epidemiology and Etiology 1006

Anatomic Considerations 1007

Pathology 1009

Squamous Carcinoma 1000
Anorectal Melanoma 1018
Adenocarcinoma 1019
Future Directions 1019

33

Cancer of the Kidney and Ureter 1023

W. MARSTON LINEHAN
WILLIAM U. SHIPLEY
DAVID R. PARKINSON

Renal Cell Carcinoma 1023
Metastatic Renal Cell Carcinoma 1033
Carcinoma of the Renal Pelvis 1042

34

Cancer of the Bladder 1052

WILLIAM R. FAIR
ZVI Y. FUKS
HOWARD I. SCHER


Epidemiology 1052
Pathology 1053
Clinical Presentation 1054
Staging Systems 1055
Approach to Treatment 1056
Treatment of Superficial Bladder Cancer 1057
Treatment of Invasive Disease 1058
Managing Advanced Disease 1067

35

Cancer of the Prostate 1073

GERALD E. HANKS
CHARLES E. MYERS
PETER T. SCARDINO

Epidemiology 1073
Natural History 1075
Anatomy and Pathology 1077
Markers of Prostate Cancer 1079



Screening	1081
Routes of Spread	1083
Imaging Studies of the Prostate and Lymph Nodes	1084
Treatment of Clinically Localized Prostate Cancer	1085
Indications for Radiation Treatment and Special Points	1088
Interstitial Radiation Therapy	1091
Results of External-Beam Irradiation	1095
Complications of Treatment	1098
Therapy for Advanced Disease	1104
Principles of Endocrine Therapy	1104
Cytotoxic Chemotherapy	1107

36

<i>Cancer of the Urethra and Penis</i>	1114
--	------

WILLIAM R. FAIR
ZVI Y. FUKS
HOWARD I. SCHER

Carcinoma of the Male Urethra	1114
Carcinoma of the Female Urethra	1117
Cancer of the Penis	1119

37

<i>Cancer of the Testis</i>	1126
-----------------------------------	------

LAWRENCE H. EINHORN
JEROME P. RICHIE
WILLIAM U. SHIPLEY

Clinical Symptoms	1126
Histology	1127
Seminoma	1128
Nonseminomatous Germ Cell Tumors	1128
Clinical Staging	1128
Treatment	1130
Prognostic Factors in Disseminated Germ Cell Tumors	1139
Extragenital Germ Cell Tumors	1142
Salvage Chemotherapy	1143
Radiation Therapy for Residual Masses of Metastatic Nonseminomatous Germ Cell Cancer	1145
Autologous Bone Marrow Transplantation	1145
Salvage Surgery	1145
Adjuvant Chemotherapy for Stage II Disease	1146
Late Consequences of Cisplatin Combination Chemotherapy	1146
Fertility	1146
Vascular Complications	1147
Bleomycin-Related Complications	1147
Leukemia	1148
Additional Topics	1148

38***Gynecologic Tumors* 1152**

WILLIAM J. HOSKINS

CARLOS A. PEREZ

ROBERT C. YOUNG

Carcinoma of the Vulva 1152

Carcinoma of the Vagina 1162

Carcinoma of the Cervix 1168

Carcinoma of the Endometrium 1195

Uterine Sarcomas 1206

Carcinoma of the Fallopian Tube 1209

Gestational Trophoblastic Disease 1212

Postirradiation Gynecologic Malignancies 1214

39***Cancer of the Ovary* 1226**

ROBERT C. YOUNG

CARLOS A. PEREZ

WILLIAM J. HOSKINS

Epidemiology 1226

Pathogenesis 1227

Histology 1229

Diagnosis and Staging 1231

Cytoreductive Surgery 1235

Radiation Therapy 1239

Chemotherapy 1245

Results of Treatment 1252

Management of Stromal and Germ Cell

Ovarian Tumors 1255

40***Cancer of the Breast* 1264**

JAY R. HARRIS

MONICA MORROW

GIANNI BONADONNA

Oncogenes and Growth Factors in Breast Cancer 1264

Screening for Breast Cancer 1265

Risk Factors 1266

Prevention of Breast Cancer 1268

Breast Biopsy 1269

Classification of Tumor Types 1272

Local and Regional Spread of Breast Cancer 1273

Pretreatment Evaluation	1277
Staging	1278
Local Treatment of Breast Carcinoma	1280
Treatment of Specific Problems in Breast Cancer	1289
In Situ Carcinoma	1297
Systemic Adjuvant Therapy	1301
Primary Chemotherapy	1314
Follow-up Examinations After Primary Therapy	1315
Treatment of Overt Metastatic Breast Cancer	1315

41

<i>Cancer of the Endocrine System</i>	1333
---------------------------------------	------

JEFFREY A. NORTON
BERNARD LEVIN
ROBERT T. JENSEN

The Thyroid Gland	1333
The Parathyroid Gland	1350
The Adrenal Gland	1352
Carcinoid Tumors	1371
Pancreatic Endocrine Tumors	1386
Management of Metastatic Disease	1413
Multiple Endocrine Neoplasia Type I	1415
Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Types IIa and IIb	1417

42

<i>Sarcomas of Soft Tissues</i>	1436
---------------------------------	------

JAMES C. YANG ELI J. GLATSTEIN
STEVEN A. ROSENBERG KAREN H. ANTMAN

Incidence	1436
Epidemiology	1437
Sites of Soft Tissue Sarcomas	1438
Pathologic Classification	1438
Benign Tumors of Soft Tissue	1443
Diagnosis	1447
Staging	1449
Natural History of Soft Tissue Sarcomas	1451
Treatment	1456
Treatment of Recurrent or Metastatic Sarcomas	1472
Quality of Life Issues	1480

43***Benign and Malignant Mesothelioma* 1489**

KAREN H. ANTMAN FREDERICK P. LI
 HARVEY I. PASS JOSEPH CORSON
 THOMAS DELANEY

Epidemiology 1489
 Malignant Pleural Mesothelioma 1491
 Malignant Peritoneal Mesothelioma 1501
 Malignant Mesothelioma of the Tunica Vaginalis Testis 1503
 Malignant Mesothelioma of the Pericardium 1503
 Benign Mesothelioma 1503

44***Sarcomas of Bone* 1509**

MARTIN M. MALAWER
 MICHAEL P. LINK
 SARAH S. DONALDSON

Classification and Types of Bone Tumors 1509
 Radiographic Evaluation and Diagnosis 1510
 Natural History 1511
 Staging Bone Tumors 1514
 Preoperative Evaluation 1515
 Biopsy Technique and Timing 1515
 Restaging After Preoperative Chemotherapy 1517
 Surgical Management of Skeletal Tumors 1519
 Chemotherapy for Bone Sarcomas 1523
 Radiation Therapy for Bone Tumors 1530
 Osteosarcoma 1534
 Chondrosarcoma 1552
 Giant Cell Tumor of Bone 1557
 Malignant Fibrous Histiocytoma 1558
 Fibrosarcoma of Bone 1558
 Chordoma 1559
 Small Round Cell Sarcomas of Bone 1560
 Lymphomas of Bone 1560

45***Cancers of the Skin* 1567**

BIJAN SAFAI

Epidemiology 1567
 Etiology and Pathogenesis of Skin Cancers 1567
 Classification of Skin Tumors 1571
 Benign Tumors Arising From Epidermal Keratinocytes 1571
 Premalignant Tumors of the Epidermis 1572
 Malignant Epidermal Tumors 1578

Cancer-Associated Gen dermatoses	1584
Tumors Arising From Epidermal Merkel's Cell	1585
Tumors Arising From Epidermal Langerhans Cells	1585
Tumors Arising From Skin Appendages	1585
Tumors of Hair Follicles	1586
Tumors of Sebaceous Glands	1587
Tumors of Apocrine Glands	1587
Tumors of Eccrine Glands	1588
Tumors Arising From the Dermis	1592
Lymphoreticular Tumors and Related Conditions	1592
Tumors Metastatic to Skin	1592
Principles of Diagnosis and Treatment	1592

46

<i>Cutaneous Melanoma</i>	1612
---------------------------------	------

CHARLES M. BALCH
ALAN N. HOUGHTON
LESTER J. PETERS

Clinical Characteristics	1612
Biology of Melanoma	1614
Epidemiology	1615
Staging Systems	1617
Prognostic Features of Melanoma	1617
Management of the Primary Melanoma	1623
Regional Metastatic Melanoma	1625
Management of In-Transit Metastases	1627
Elective Lymph Node Dissection	1628
Metastatic Melanoma at Distant Sites	1632

47

<i>Intraocular Melanomas</i>	1662
------------------------------------	------

JOSE A. SAHEL
JOHN D. EARLE
DANIEL M. ALBERT

Epidemiology	1662
Etiology and Histogenesis	1663
Histopathology, Prognostic Parameters, and Natural History	1663
Distinguishing Features of Iris Melanomas	1666
Diagnosis of Uveal Melanomas	1667
Treatment of Uveal Melanomas	1668
Treatment of Choroidal and Ciliary Body Melanomas	1669
Treatment of Tumors With Extrascleral Extension	1672
Treatment of Iris Melanoma	1672

48***Neoplasms of the Central Nervous System* 1679**

VICTOR A. LEVIN
 PHILIP H. GUTIN
 STEVEN LEIBEL

- Incidence and Classification 1679
- Tumorigenesis 1680
- Genetic Factors 1681
- Chemical Induction and Epidemiology 1681
- Viral Infection and CNS Neoplasia 1682
- Trauma and CNS Neoplasia 1682
- CNS Neoplasia After Radiation, Chemotherapy, and Immunosuppression 1682
- Anatomic and Clinical Considerations 1682
- Neurodiagnostic Tests 1688
- Surgery 1694
- Radiation Therapy 1695
- Chemotherapy 1699
- Cerebral Astrocytomas 1700
- Brain Stem Gliomas 1706
- Cerebellar Astrocytomas 1707
- Optic, Chiasmal, and Hypothalamic Gliomas 1707
- Oligodendrogliomas 1709
- Ependymoma 1710
- Meningiomas 1712
- Primary CNS Lymphoma 1715
- Primitive Neuroepithelial Tumors 1716
- Medulloblastoma 1717
- Pineal Region Tumors 1720
- Pituitary Adenomas 1723
- Craniopharyngiomas 1724
- Cerebellopontine Angle Neurilemmomas 1725
- Glomus Jugulare Tumors 1726
- Chordomas 1726
- Hemangioblastomas and Hemangiomas 1727
- Choroid Plexus Papilloma and Carcinoma 1728
- Spinal Axis Tumors 1729

49***Solid Tumors of Childhood* 1738**

PHILIP A. PIZZO DANIEL M. HAYS
 MARC E. HOROWITZ LARRY E. KUN
 DAVID G. POPLACK

- Epidemiology of Childhood Cancer 1738
- Genetics and Biology 1739
- Unusual Clinical Manifestations 1741
- Prognostic Factors 1742
- Management of Pediatric Tumors 1742

Wilms' Tumor	1744
Neuroblastoma	1749
Retinoblastoma	1756
Primary Hepatic Tumors	1760
Germ Cell Tumors	1765
Rhabdomyosarcoma	1772
Ewing's Sarcoma and Peripheral Primitive Neuroectodermal Tumor	1778
Less Common Sarcomas	1783
Histiocytoses	1786
Carcinomas and Other Less Common Tumors of Childhood	1789

50

Leukemias and Lymphomas of Childhood 1792

DAVID C. POPLACK IAN T. MACRATH
LARRY E. KUN PHILIP A. PIZZO

Epidemiology and Etiology	1792
Acute Lymphoblastic Leukemia	1794
Acute Myelogenous Leukemia	1803
Neonatal Leukemia	1804
Chronic Myelogenous Leukemia	1804
Non-Hodgkin's Lymphoma	1805
Hodgkin's Disease	1814

51

Hodgkin's Disease 1819

VINCENT T. DEVITA, JR
SAMUEL HELLMAN
ELAINE S. JAFFE

History	1819
Etiology and Epidemiology	1820
Pathology Classification	1820
Natural History and Disease Evolution	1825
Diagnosis and Staging	1826
Treatment	1829

52

Lymphocytic Lymphomas 1859

DAN L. LONGO PETER MAUCH
VINCENT T. DEVITA, JR WALTER J. URBA
ELAINE S. JAFFE

Epidemiology	1859
Etiology	1860
Microscopic and Functional Anatomy of Normal Lymphoid Tissues	1864
Pathology of Lymphocytic Lymphomas	1871

Differential Diagnosis	1882
Natural History and Staging of the Lymphocytic Lymphomas	1885
Immunologic Abnormalities in Patients With Lymphoma	1891
Treatment of Lymphocytic Lymphomas	1891

53

<i>Cutaneous Lymphomas</i>	1928
PAUL A. BUNN, JR	
RICHARD T. HOPPE	
Classification of T-Cell Malignancies	1929
Clinical Features of Adult T-Cell Leukemia-Lymphoma	1930
Clinical Features of Low-Grade T-Cell Lymphomas	1930
Treatment	1932

54

<i>Acute Leukemia</i>	1938
MICHAEL J. KEATING	
ELIHU ESTEY	
HAGOP KANTARJIAN	
Etiology	1938
Secondary Leukemias	1939
Diagnosis and Classification	1940
Biochemical and Genetic Irregularities	1946
Biologic Features of Acute Leukemia	1947
Treatment	1948

55

<i>Chronic Leukemias</i>	1965
ALBERT B. DEISSEROTH	HAGOP KANTARJIAN
MICHAEL ANDREEFF	ISSA F. KHOURI
RICHARD CHAMPLIN	MOSHE TALPAZ
MICHAEL J. KEATING	
Chronic Lymphocytic Leukemia	1965
Prolymphocytic Leukemia	1971
Hairy Cell Leukemia	1971
T-Cell Chronic Lymphocytic Leukemia	1971
Chronic Myelogenous Leukemia	1971
Conclusion	1979

56

<i>Plasma Cell Neoplasms</i>	1984
SYDNEY E. SALMON	
J. ROBERT CASSADY	
History	1986
Incidence and Mortality	1987

Pathogenesis	1987
Pathology	1989
Diagnosis and Clinical Staging of Myeloma	1992
Treatment	1994
Complications and Special Problems	2007
Other Plasma Cell Neoplasms	2013
Perspective	2017

57

Paraneoplastic Syndromes 2026

PAUL A. BUNN, JR
E. CHESTER RIDGWAY

Etiology and Pathogenesis of Paraneoplastic Syndromes	2027
Differential Diagnosis	2027
Endocrinologic Manifestations of Malignancy	2027
Neurologic Manifestations of Malignancy	2041
Hematologic Manifestations of Malignancy	2046
Renal Manifestations of Malignancy	2053
Paraneoplastic Lesions Involving the Skin	2054
Gastrointestinal Paraneoplastic Syndromes	2060
Miscellaneous Paraneoplastic Syndromes	2061

58

Cancer of Unknown Primary Site 2072

F. ANTHONY GRECO
JOHN D. HAINSWORTH

Poorly Differentiated Neoplasms of Unknown Primary Site	2073
Adenocarcinoma of Unknown Primary Site	2074
Squamous Carcinoma of Unknown Primary Site	2077
Poorly Differentiated Carcinoma and Adenocarcinoma of Unknown Primary Site	2079
Special Issues in Carcinoma of Unknown Primary Origin	2088
Summary	2091

59

Cancer in AIDS 2093

JUDITH E. KARP
JEROME E. GROOPMAN
SAMUEL BRODER

AIDS-Related Kaposi's Sarcoma	2094
AIDS-Related Anogenital Cancers	2101
AIDS-Related Non-Hodgkin's Lymphomas	2101
Future Directions: Prevention	2108

60**Oncologic Emergencies** 2111**SECTION 1 Superior Vena Cava Syndrome** 2111

JOACHIM YAHALOM

Anatomy and Pathophysiology 2111

Etiology and Natural History 2111

Diagnostic Procedures 2113

Treatment 2114

Management Recommendations 2116

SECTION 2 Spinal Cord Compression 2118

THOMAS F. DELANEY

EDWARD H. OLDFIELD

Pathophysiology 2118

Clinical Presentation 2119

Diagnostic Evaluation 2120

Treatment 2121

Conclusion 2126

SECTION 3 Metabolic Emergencies 2128

RAYMOND P. WARRELL, JR

Hypercalcemia 2128

Hyperuricemia 2134

Tumor Lysis Syndrome 2135

Hypoglycemia 2136

Adrenal Failure 2136

Lactic Acidosis 2137

SECTION 4 Surgical Emergencies 2141

ALAN R. BAKER

Diagnosis and Consultation 2141

Deciding to Operate 2142

Urgent Conditions 2142

Deciding on Aggressive or Conservative Management 2157

Nutrition and Other Support 2157

SECTION 5 Urologic Emergencies 2159

PAUL RUSSO

Bladder Hemorrhage 2159

Obstructive Uropathy 2161

Urinary Tract Infection 2166

Priapism 2168

61

Treatment of Metastatic Cancer 2170

SECTION 1 Treatment of Metastatic Cancer to the Brain 2170

DONALD C. WRIGHT
THOMAS F. DELANEY
JAN C. BUCKNER

- Classification and Epidemiology of Cerebral Metastases 2170
- Pathogenesis and Pathophysiology of Cerebral Metastases 2171
- Clinical Aspects of Brain Metastases 2173
- Principles of Management 2175
- Cerebral Metastases: Results of Therapy 2178
- Cerebral Metastases: Summary 2183

SECTION 2 Treatment of Metastatic Cancer to the Lung 2186

HARVEY I. PASS

- History 2186
- Pathophysiology 2186
- Surgical Resection of Pulmonary Metastases 2190
- Prognostic Factors for the Resection of Pulmonary Metastases 2191
- Other Prognostic Variables Examined 2193
- Technique of Pulmonary Metastasectomy 2194
- Reoperative Metastasectomy 2196
- Metastasectomy for Specific Histologies 2196

SECTION 3 Treatment of Metastatic Cancer to the Liver 2201

JOHN E. NIEDERHUBER
WILLIAM D. ENSMINGER

- Liver Metastases From Colorectal Cancer 2201
- Hepatic Resection of Secondary Tumors 2204
- Systemic Chemotherapy 2211
- Regional Chemotherapy 2211

SECTION 4 Treatment of Metastatic Cancer to Bone 2225

MARTIN M. MALAWER
THOMAS F. DELANEY

- Incidence and Anatomic Sites of Skeletal Metastases 2225
- General Considerations 2226
- Mechanism and Pathogenesis of Skeletal Metastasis 2226
- Radiographic Diagnosis and Evaluation of Metastases 2227
- Bone Scintigraphy 2228
- Computed Tomography 2230
- Magnetic Resonance Imaging 2231
- Angiography 2231
- Biomechanical and Healing Considerations of Tumor Defects and Pathologic Fractures 2231
- Preoperative Evaluation, Local Staging, and Biopsy Considerations 2232
- Biopsy: Technique and Considerations 2232
- Principles of Surgical Treatment for Skeletal Metastasis 2233
- General Principles of Radiation Therapy for Skeletal Metastasis 2234
- Specific Tumors: Unique Clinical and Management Considerations 2237
- Specific Anatomic Sites: Clinical, Surgical, and Radiotherapeutic Considerations 2238

SECTION 5	<i>Treatment of Malignant Pleural and Pericardial Effusions</i>	2246
	HARVEY I. PASS	
	Pleural Effusions	2246
	Pericardial Effusions	2251

SECTION 6	<i>Treatment of Malignant Ascites</i>	2255
	ALAN R. BAKER	
	JEFFREY S. WEBER	
	Malignant Ascites	2255

62

<i>Bone Marrow Dysfunction in the Cancer Patient</i>	2262
---	-------------

SECTION 1	<i>Use of Blood and Blood Products</i>	2262
	RALPH O. WALLERSTEIN, JR	
	ALBERT B. DEISSEROTH	
	Erythrocyte Transfusion	2262
	Transfusion-Induced Graft-Versus-Host Disease	2264
	Transmission of Infectious Agents	2266
	Platelet Transfusions	2267
	Granulocyte Transfusion	2269
	Intravenous Immunoglobulin	2269
	Apheresis	2270
	Bone Marrow Transplantation	2271
	Conclusion	2272

SECTION 2	<i>Hematopoietic Growth Factors</i>	2275
	JANICE L. GABRILOVE	
	DAVID W. GOLDE	
	Humoral Regulation of Hematopoiesis	2275
	Principles of Therapy With Hematopoietic Growth Factors	2276
	Erythropoietin	2276
	Granulocyte Colony-Stimulating Factor	2278
	Granulocyte-Macrophage Colony-Stimulating Factor	2282
	Macrophage Colony-Stimulating Factor	2288
	Interleukin-3	2289
	Hematopoietic Growth Factors in Combination	2289

SECTION 3	<i>Infections in the Cancer Patient</i>	2292
	PHILIP A. PIZZO	ALISON C. FREIFELD
	JOEL MEYERS*	THOMAS WALSH
	Impaired Host Defenses of the Cancer Patient	2292
	Evaluation and Management of the Febrile Cancer Patient	2296
	Treatment of Infectious Complications	2309
	Preventing Infection in Cancer Patients	2329

* Deceased.

63

Adverse Effects of Treatment 2338

SECTION 1	<i>Antiemetic Therapy</i>	2338
	RICHARD J. GRALLA	
	Physiology and Pharmacology in Controlling Emesis	2338
	Emetic Problems	2339
	Control of Emesis and Patient Characteristics	2340
	New Antiemetic Agents	2341
	Standard Antiemetic Agents	2343
	Antiemetic Combinations	2345
	Controlling Emesis in Special Situations	2346
	Cost of Treating Emesis	2346
	Conclusion	2347

SECTION 2	<i>Miscellaneous Toxicities</i>	2349
	RAYMOND B. WEISS	
	NICHOLAS J. VOGELZANG	
	Nephrotoxicity	2349
	Neurotoxicity	2351
	Hepatotoxicity	2354
	Hypersensitivity Reactions	2355
	Vascular Toxicity	2356

SECTION 3	<i>Cystitis</i>	2358
	MCCLELLAN M. WALTHER	
	Chemical Cystitis	2358
	Intravesical Phototherapy	2360
	Radiation	2361
	Antibiotics	2361

SECTION 4	<i>Pulmonary Toxicity</i>	2362
	DIANE E. STOVER	
	Radiation-Induced Pulmonary Toxicity	2362
	Chemotherapy-Induced Pulmonary Toxicity	2365

SECTION 5	<i>Cardiac Complications of Cancer Therapy</i>	2370
	LAUREL J. STEINHERZ	
	JOACHIM YAHALOM	
	Chemotherapy	2370
	Radiation-Induced Heart Disease	2377
	Conclusion	2380

SECTION 6	<i>Oral Complications of Cancer Therapy</i>	2385
	STEPHEN T. SONIS	
	Oral Complications of Radiation Therapy	2385
	Oral Complications of Cancer Chemotherapy	2387

SECTION 7	Hair Loss	2394
	CLAUDIA A. SEIPP	
	Head Coverings	2394
	Prevention of Alopecia	2394
SECTION 8	Gonadal Dysfunction	2395
	RICHARD J. SHERINS	
	Chemotherapy Effects in Adult Men	2396
	Chemotherapy Effects in Adult Women	2398
	Chemotherapy Effects in Children	2399
	Radiation Therapy	2399
	Techniques to Protect Fertility	2400
	Genetic Concerns	2401
	Pregnancy Outcomes	2402
	Counseling	2403
SECTION 9	Secondary Cancers	2407
	MARGARET A. TUCKER	
	Methods of Studying Secondary Malignancies	2407
	Individual Treatment Modalities	2408
	Secondary Tumors in Pediatric, Hodgkin's Disease, and Breast Cancer Populations	2410
	Host Factors	2414
	Conclusion	2415

64

Supportive Care and the Quality of Life of the Cancer Patient 2417

SECTION 1	Management of Cancer Pain	2417
	KATHLEEN M. FOLEY	
	Barriers to Cancer Pain Relief	2417
	Epidemiology	2418
	Definition and Types of Cancer Pain	2419
	Impact of a Comprehensive Examination on the Management of Cancer Pain	2427
	Management of Cancer Pain	2428
	Psychological Approaches	2437
	Anesthetic and Neurosurgical Approaches	2437
	Physiatric Approaches	2444
	Algorithm for Cancer Pain Management	2444
	Future Directions	2445
SECTION 2	Psychosocial and Ethical Issues in the Care of Cancer Patients	2448
	MARGUERITE S. LEDERBERG	
	MARY JANE MASSIE	
	Psychosocial Issues: Historical Background	2448
	Psychological Impact of Cancer	2449
	Long-Term Survivors	2457
	The "Worried Well": Psychological Problems in High-Risk Groups	2457
	Management of Grief	2458

Stresses on Oncologists	2459
Psychosocial and Behavioral Factors in Cancer Risk and Survival	2460
Common Ethical Dilemmas Confronting the Caregiver in Cancer	2461

SECTION 3 Sexual Problems 2464

LESLIE R. SCHOVER
DROGO K. MONTAGUE
WENDY S. SCHAIN

Psychological Impact of Cancer on Sexual Function	2465
Physiologic Impact of Systemic Therapies	2465
Physiologic Impact of Local Therapies	2467
Assessing Sexual Function in Cancer Patients	2472
Treating Sexual Problems in Cancer Patients	2475

SECTION 4 Nutritional Support 2480

JOHN M. DALY
MICHAEL H. TOROSIAN

Cancer Cachexia	2481
Effects of Antitumor Therapy on Nutrition	2485
Consequences of Malnutrition in the Cancer Patient	2485
Nutritional Assessment	2486
Preoperative Nutritional Support	2487
Nutrition in the Perioperative Period	2491
Nutrition and Host Metabolism	2492
Nutrition and Immunity	2495
Effects of Preoperative Nutritional Support	2496
Nutritional Support With Chemotherapy and Radiation Therapy	2499

SECTION 5 Specialized Care of the Terminally Ill 2501

FRANK J. BRESCIA

Philosophy of Care	2501
Symptom Control	2502
Terminal Events	2503
Predicting Survival	2504
Challenges and Questions	2504
Conclusion	2506

SECTION 6 Dealing With the Dying Patient 2508

DONNA SAMMARINO

Institutional Obstacles	2508
Personal Obstacles	2509
The Dying Process	2509
Medical and Nursing Needs of the Terminally Ill	2510
Psychoemotional Needs of the Terminally Ill	2510
What Can Be Done?	2511

SECTION 7 Providing Community Resources for Cancer Patients 2513

GRACE H. CHRIST MATTHEW LOSCALZO
ROSEMARY T. MOYNIHAN LOIS L. WEINSTEIN

Prevalence of Needs	2513
Barriers to the Use of Community Resources	2515

New Interventions	2515
Services for Evolving Needs	2517
Appendix: Resources and Services	2525

65

<i>Genetic Counseling of the Cancer Patient</i>	2529
---	------

JOHN J. MULVIHILL

Counseling About Genetic Causes of Cancer	2529
Genetic Counseling at the Beginning of Therapy	2535
Genetic Counseling After Therapy Ends	2535
Conclusion	2537

66

<i>Evaluation and Management of Disability: Rehabilitation Aspects of Cancer</i>	2538
--	------

LYNN H. GERBER JESSIE WHITEHURST
STEPHEN LEVINSON DONNA SCHEIB
JEANNE E. HICKS BARBARA C. SONIES
PATRICE GALLELLI

The Role of Rehabilitation	2539
The Cancer Rehabilitation Team	2540
Functional Evaluation	2541
Common Functional Impairments in Oncology	2541
Rehabilitation and Management of Specific Tumors	2551

67

<i>Practical Guide to Chemotherapy Administration for Physicians and Oncology Nurses</i>	2570
--	------

ELLEN J. GALLINA

Drug Administration	2571
Regional Drug Administration	2572
Cutaneous Reactions Associated With Chemotherapy Administration	2573
Handling and Disposal of Chemotherapy	2579
Conclusion	2580

68

<i>Information Systems in Oncology</i>	2581
--	------

SECTION 1 Information Retrieval Systems 2581

SUSAN MOLLOY HUBBARD

Historical Perspective	2581
The PDQ System	2582
CancerFax	2587
New Initiatives	2587
Clinical Information Systems for Decision Support	2587

SECTION 2	Research Data Management	2590
	COLIN B. BEGG	
	Principles of Study Design	2591
	Research Data Management Methodology	2592
	Multiinstitutional Studies	2595
	Conclusions	2596

69

Newer Approaches to Cancer Treatment 2598

SECTION 1	Gene Therapy of Cancer	2598
	STEVEN A. ROSENBERG	
	Introduction of Foreign Genes Into Mammalian Cells	2598
	Cancer Therapy Using Gene-Modified Tumor-Infiltrating Lymphocytes	2599
	Gene Therapy of Cancer Using Tumor Transduced With Cytokine Genes to Increase Immunogenicity	2608
	Other Approaches to Gene Therapy	2610
	Conclusions	2612
SECTION 2	Three-Dimensional Conformal Radiotherapy	2614
	ZVI Y. FUKS	
	SAMUEL HELLMAN	
	Biologic Basis of Three-Dimensional Conformal Radiotherapy	2614
	Three-Dimensional Simulation Procedures	2616
	Biologic Target Volume and Critical Organs	2617
	Selection of Beams and Calculation of Dose Distributions	2617
	Quantitative Evaluation of Treatment Plans	2617
	Computer-Aided Optimization of Treatment Planning	2619
	Three-Dimensional Conformal Therapy Delivery Systems	2619
	Preliminary Clinical Experience	2620
	Prospects for the Future	2622
SECTION 3	Immunotoxin Therapy	2624
	ELLEN S. VITETTA	
	JONATHAN W. UHR	
	PHILIP E. THORPE	
	General Principles	2624
	Components of an Immunotoxin	2624
	Preclinical Evaluation	2628
	Clinical Trials	2629
SECTION 4	Differentiating Agents	2636
	CHARLES W. YOUNG	
	RAYMOND P. WARRELL, JR	
	Retinoids	2637
	1,25-Dihydroxyvitamin D ₃	2641
	Low-Dose Cytosine Arabinoside	2642
	Tiazofurin	2642
	Planar-Polar Inducers	2642

Cyclic AMP Modulation	2643
Conclusions	2643

SECTION 5	<i>Antisense Inhibition of Gene Expression</i>	2646
	C.A. STEIN	
	Historical Background	2646
	Classes of Oligodeoxynucleotides	2646
	Interactions of Oligonucleotides With Cells	2647
	Pharmacology of Oligodeoxynucleotides	2647
	Mechanism of the Antisense Effect	2648
	Sequence-Specific Antisense Inhibition of Genetic Expression	2648

SECTION 6	<i>Overcoming the Multidrug-Resistant Phenotype</i>	2655
	WILLIAM S. DALTON	
	Structure and Function of P-Glycoprotein	2656
	Methods of Detection of Multidrug Resistance	2657
	Multidrug Resistance in Hematologic Tumors	2658
	Multidrug Resistance in Solid Tumors	2660
	Reversing Multidrug Resistance	2661
	Conclusions	2664

SECTION 7	<i>The Application of Circadian Chronobiology to Cancer Chemotherapy</i>	2666
	WILLIAM J.M. HRUSHESKY	
	GEORG A. BJARNASON	
	Chronobiology	2666
	Cytokinetic Rhythms	2668
	Timing of Chemotherapy	2670
	Chronobiologic Data for Chemotherapy Agents	2671
	Practical Implications of Circadian Effects	2682

SECTION 8	<i>Photodynamic Therapy</i>	2687
	HARVEY I. PASS	
	THOMAS F. DELANEY	
	Mechanism of Photodynamic Therapy	2687
	Components of Photodynamic Therapy	2687
	Mechanisms of Photodynamic Therapy	2688
	Photodynamic Therapy for Malignancies	2689
	Conclusions	2697

SECTION 9	<i>Radiation Sensitizers</i>	2701
	CLAIR J. BEARD	
	C. NORMAN COLEMAN	
	TIMOTHY J. KINSELLA	
	Therapeutic Strategies for Hypoxic Cells	2701
	Hypoxic Cell Sensitizers	2704
	Treatment With Radiation Sensitizers	2707
	Conclusions	2710

SECTION 10 Heavy Particle Beam Radiation Therapy 2713

THOMAS W. GRIFFIN
MARY AUSTIN-SEYMOUR

Bi logic Effects of Heavy Particle Beams 2713

Physical Effects of Particle Beams 2714

Fast Neutron Clinical Studies 2714

Charged Particle Clinical Studies 2720

Protons and Helium Ions 2720

Heavy Charged Particles 2721

Pi Mesons 2722

Boron Neutron-Capture Therapy 2722

SECTION 11 Hyperthermia 2725

JAMES R. OLESON

Biologic Background 2725

Technical Aspects 2727

Clinical Results 2728

Trends in Hyperthermia 2730

70

Unsound Methods of Cancer Treatment 2734

GREGORY A. CURT

Definition and Magnitude of the Problem 2734

Treatment Regulation 2735

The Era of Unsound Devices 2736

The Era of Unsound Drugs 2736

Unsound Cancer Treatments Popular Today 2740

Investigating Alternative Therapies 2743

The Simonton Method: An Unproven Adjunct to Cancer Treatment 2744

Patient Characteristics and the Role of Health Providers 2745

Index 1